Related Experiment Videos
The bisphosphonate ibandronate improves implant integration in osteopenic ovariectomized rats
A H A Kurth1, C Eberhardt, S Müller
1Department of Orthopaedic Surgery, University Hospital Frankfurt, Marienburgstr. 2, 60528 Frankfurt/Main, Germany. A.Kurth@em.uni-frankurt.de
Bone
|June 7, 2005
Summary
Bisphosphonates like ibandronate improve implant osseointegration in osteoporotic rats. This study shows ibandronate enhances hydroxyapatite-coated implant stability in ovariectomized rats, offering potential for osteoporosis patients.
Area of Science:
- Biomaterials Science
- Orthopedic Surgery
- Pharmacology
Background:
- Osteoporosis significantly impairs osseointegration, the process by which bone integrates with implants.
- Bisphosphonates are a class of drugs that inhibit bone resorption, making them a potential therapeutic strategy for improving bone quality and implant stability in osteoporotic patients.
- Hydroxyapatite (HA)-coated implants are commonly used in orthopedic and dental applications, and their osseointegration can be affected by systemic bone health.
Purpose of the Study:
- To investigate the effect of the bisphosphonate ibandronate on the osseointegration of titanium implants in an ovariectomized (OVX) rat model of osteoporosis.
- To evaluate whether ibandronate administration can counteract the negative impact of OVX-induced osteopenia on implant osseointegration, particularly for HA-coated implants.
Main Methods:
- Eighty-four rats underwent either OVX or sham surgery, followed by implantation of titanium-only or HA-coated titanium femoral implants.
- OVX rats received daily subcutaneous injections of saline, 1 microg/kg ibandronate, or 25 microg/kg ibandronate for four weeks.
- Bone mineral density (BMD) and osseointegration percentage (OIS) were assessed using histomorphometric analysis.
Main Results:
- Ibandronate treatment significantly increased lumbar spine BMD in OVX rats to levels comparable to sham-operated controls.
- For titanium-only implants, no significant difference in OIS was observed between groups.
- For HA-coated implants, OIS was significantly higher in ibandronate-treated OVX rats (113.5% and 185% increase for low and high doses, respectively) compared to OVX controls. OVX controls showed a 56.5% lower OIS than sham controls.
Conclusions:
- OVX-induced osteopenia detrimentally affects the osseointegration of HA-coated titanium implants.
- Ibandronate administration, at doses relevant to clinical osteoporosis and metastatic bone disease treatment, effectively reverses the negative impact of osteopenia on HA-coated implant osseointegration.
- Ibandronate shows promise as an adjunctive therapy to improve implant success rates in patients with osteoporosis and metastatic bone disease.